New drug trial offers hope for inherited blindness
NCT ID NCT07408232
First seen Feb 15, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study tests a new drug called OCT-980 for people with a genetic form of retinitis pigmentosa, an eye disease that leads to vision loss. The trial first checks safety in healthy volunteers, then tests the drug in patients to see if it can slow or stop the disease. About 32 people will take part in this early-stage study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia
Conditions
Explore the condition pages connected to this study.